Experimental Novartis Cardiac Drug May Also Stop Lung Cancer

Aug 28, 2017

A Novartis Phase III study evaluating an anti-inflammatory drug for cardiac patients not only revealed a significant reduction in the risk of major adverse cardiovascular events, but also that the drug may prevent lung cancer.

The ACZ885 (canakinumab) CANTOS study showed a 15% reduction of major adverse cardiovascular events (MACE) in people with a prior heart attack and inflammatory atherosclerosis, and surprisingly also revealed a 77% reduction in lung cancer mortality and 67% reduction in lung cancer cases.

With more than 10,000 patients enrolled in the study over the last six years, CANTOS was one of the largest and longest-running clinical trials in Novartis' history.

Novartis plans to initiate a new Phase III trial based on its early lung cancer findings, while seeking seeking regulatory approval of ACZ885 in the cardiovascular setting.

Read the press release


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments